Utility of green chemistry for sustainable fluorescence derivatization approach for spectrofluorimetric quantification of Darolutamide as antineoplastic drug in pharmaceutical formulation and spiked human plasma
Darolutamide is an oral nonsteroidal androgen receptor antagonist used to delay the process of prostate cancer to metastatic disease and to increase the quality of life for people with advanced prostate cancer. Here, a second spectrofluorimetric method was advanced for quantifying Darolutamide in ph...
Gespeichert in:
Veröffentlicht in: | Luminescence (Chichester, England) England), 2024-03, Vol.39 (3), p.e4704-n/a |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | n/a |
---|---|
container_issue | 3 |
container_start_page | e4704 |
container_title | Luminescence (Chichester, England) |
container_volume | 39 |
creator | Salem, Hesham Abdelmajed, Mahmoud A. Rabiey, Mahmoud Saied, Omar Amir, Michael Abdelgalil, Mahmoud |
description | Darolutamide is an oral nonsteroidal androgen receptor antagonist used to delay the process of prostate cancer to metastatic disease and to increase the quality of life for people with advanced prostate cancer. Here, a second spectrofluorimetric method was advanced for quantifying Darolutamide in pharmaceutical formulation and spiked human plasma. This method depends on the fluorescence derivatization of Darolutamide with 4‐chloro‐7‐nitrobenzo‐2‐oxa‐1,3‐diazole (NBD‐Cl) at 75°C in a (pH 9) of borate buffer to produce a fluorescent derivative that can be detected at 520 nm after excitation at 460 nm. The method has been validated using ICH criteria, and it demonstrated linearity in the range 5–200 ng ml−1. The limit of detection (LOD) and limit of quantitation (LOQ) were 1.15 and 3.84 nm, respectively. The proposed method was applied precisely and accurately for quantifying Darolutamide within the pharmaceutical formulation and spiking human plasma without any interferences. Moreover, the method's sustainability was evaluated and compared with the published method using two greenness assessment tools termed analytical eco‐scale and Analytical GREEnness (AGREE). These findings suggest that the method is more sustainable than the published method.
Darolutamide is an oral nonsteroidal androgen used to delay the process of prostate cancer. A spectrofluorometric method was advanced for quantifying Darolutamide in pharmaceutical formulation and spiked human plasma. The method depends on the fluorescence derivatization of Darolutamide with NBD‐Cl. |
doi_str_mv | 10.1002/bio.4704 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2937336387</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2979403465</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3494-83072cc9a7b880d8f33d98defb4d61e65ed0d799edf7e4abe156aace1a55263f3</originalsourceid><addsrcrecordid>eNp1kdtqFTEUhgdRbK2CTyABb7yZmplkTpdaT4VCb-z1sCZZ6U7NTKY5KLuv2Rdy7e5tBcFASEi-9a_DXxSvK35acV6_n6w_lR2XT4rjqqnrsqulePp4F81R8SLGG85527bD8-JI9FLQao-L-6tknU1b5g27DogLUxucbUxhy4wPLOaYwC4wOWTGZR8wKlwUMo3B_oRk72j7hcG6Bg9qsw9aUaXgH3g7YwpWsdsMS7LGqj1P6T5B8C4nmK1GBpHt_hf0q4OYKECHfM3swtYNhBkUZnoEt9OfszskXTTlsj9Qs02egViKneFl8cyAi_jqcJ4UV18-fz_7Vl5cfj0_-3BRKiEHWfaCd7VSA3RT33PdGyH00Gs0k9RthW2DmutuGFCbDiVMWDUtUCEVNE3dCiNOind7XWr9NmNMIw1OoXNAbeQ41oPoaMii7wh9-w9643NYqDqiukFyIdvmr6AKPsaAZlxpfhC2Y8XHndEjGT3ujCb0zUEwTzPqR_CPswSUe-CXdbj9r9D48fzyQfA3PMW50g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2979403465</pqid></control><display><type>article</type><title>Utility of green chemistry for sustainable fluorescence derivatization approach for spectrofluorimetric quantification of Darolutamide as antineoplastic drug in pharmaceutical formulation and spiked human plasma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Salem, Hesham ; Abdelmajed, Mahmoud A. ; Rabiey, Mahmoud ; Saied, Omar ; Amir, Michael ; Abdelgalil, Mahmoud</creator><creatorcontrib>Salem, Hesham ; Abdelmajed, Mahmoud A. ; Rabiey, Mahmoud ; Saied, Omar ; Amir, Michael ; Abdelgalil, Mahmoud</creatorcontrib><description>Darolutamide is an oral nonsteroidal androgen receptor antagonist used to delay the process of prostate cancer to metastatic disease and to increase the quality of life for people with advanced prostate cancer. Here, a second spectrofluorimetric method was advanced for quantifying Darolutamide in pharmaceutical formulation and spiked human plasma. This method depends on the fluorescence derivatization of Darolutamide with 4‐chloro‐7‐nitrobenzo‐2‐oxa‐1,3‐diazole (NBD‐Cl) at 75°C in a (pH 9) of borate buffer to produce a fluorescent derivative that can be detected at 520 nm after excitation at 460 nm. The method has been validated using ICH criteria, and it demonstrated linearity in the range 5–200 ng ml−1. The limit of detection (LOD) and limit of quantitation (LOQ) were 1.15 and 3.84 nm, respectively. The proposed method was applied precisely and accurately for quantifying Darolutamide within the pharmaceutical formulation and spiking human plasma without any interferences. Moreover, the method's sustainability was evaluated and compared with the published method using two greenness assessment tools termed analytical eco‐scale and Analytical GREEnness (AGREE). These findings suggest that the method is more sustainable than the published method.
Darolutamide is an oral nonsteroidal androgen used to delay the process of prostate cancer. A spectrofluorometric method was advanced for quantifying Darolutamide in pharmaceutical formulation and spiked human plasma. The method depends on the fluorescence derivatization of Darolutamide with NBD‐Cl.</description><identifier>ISSN: 1522-7235</identifier><identifier>EISSN: 1522-7243</identifier><identifier>DOI: 10.1002/bio.4704</identifier><identifier>PMID: 38433336</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>4-Chloro-7-nitrobenzofurazan ; Androgen receptors ; Antineoplastic Agents ; Blood plasma ; Buffers (chemistry) ; Cancer ; Darolutamide ; Drug Compounding ; Fluorescence ; fluorescence derivatization ; Green chemistry ; green spectrofluorimetric method ; Humans ; Male ; Metastases ; NBD‐Cl ; Pharmaceuticals ; Prostate cancer ; Prostatic Neoplasms ; Pyrazoles ; Quality of Life ; Spectrofluorimetry ; Spectrometry, Fluorescence ; Sustainability</subject><ispartof>Luminescence (Chichester, England), 2024-03, Vol.39 (3), p.e4704-n/a</ispartof><rights>2024 John Wiley & Sons Ltd.</rights><rights>2024 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3494-83072cc9a7b880d8f33d98defb4d61e65ed0d799edf7e4abe156aace1a55263f3</citedby><cites>FETCH-LOGICAL-c3494-83072cc9a7b880d8f33d98defb4d61e65ed0d799edf7e4abe156aace1a55263f3</cites><orcidid>0000-0002-6467-849X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fbio.4704$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fbio.4704$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38433336$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Salem, Hesham</creatorcontrib><creatorcontrib>Abdelmajed, Mahmoud A.</creatorcontrib><creatorcontrib>Rabiey, Mahmoud</creatorcontrib><creatorcontrib>Saied, Omar</creatorcontrib><creatorcontrib>Amir, Michael</creatorcontrib><creatorcontrib>Abdelgalil, Mahmoud</creatorcontrib><title>Utility of green chemistry for sustainable fluorescence derivatization approach for spectrofluorimetric quantification of Darolutamide as antineoplastic drug in pharmaceutical formulation and spiked human plasma</title><title>Luminescence (Chichester, England)</title><addtitle>Luminescence</addtitle><description>Darolutamide is an oral nonsteroidal androgen receptor antagonist used to delay the process of prostate cancer to metastatic disease and to increase the quality of life for people with advanced prostate cancer. Here, a second spectrofluorimetric method was advanced for quantifying Darolutamide in pharmaceutical formulation and spiked human plasma. This method depends on the fluorescence derivatization of Darolutamide with 4‐chloro‐7‐nitrobenzo‐2‐oxa‐1,3‐diazole (NBD‐Cl) at 75°C in a (pH 9) of borate buffer to produce a fluorescent derivative that can be detected at 520 nm after excitation at 460 nm. The method has been validated using ICH criteria, and it demonstrated linearity in the range 5–200 ng ml−1. The limit of detection (LOD) and limit of quantitation (LOQ) were 1.15 and 3.84 nm, respectively. The proposed method was applied precisely and accurately for quantifying Darolutamide within the pharmaceutical formulation and spiking human plasma without any interferences. Moreover, the method's sustainability was evaluated and compared with the published method using two greenness assessment tools termed analytical eco‐scale and Analytical GREEnness (AGREE). These findings suggest that the method is more sustainable than the published method.
Darolutamide is an oral nonsteroidal androgen used to delay the process of prostate cancer. A spectrofluorometric method was advanced for quantifying Darolutamide in pharmaceutical formulation and spiked human plasma. The method depends on the fluorescence derivatization of Darolutamide with NBD‐Cl.</description><subject>4-Chloro-7-nitrobenzofurazan</subject><subject>Androgen receptors</subject><subject>Antineoplastic Agents</subject><subject>Blood plasma</subject><subject>Buffers (chemistry)</subject><subject>Cancer</subject><subject>Darolutamide</subject><subject>Drug Compounding</subject><subject>Fluorescence</subject><subject>fluorescence derivatization</subject><subject>Green chemistry</subject><subject>green spectrofluorimetric method</subject><subject>Humans</subject><subject>Male</subject><subject>Metastases</subject><subject>NBD‐Cl</subject><subject>Pharmaceuticals</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms</subject><subject>Pyrazoles</subject><subject>Quality of Life</subject><subject>Spectrofluorimetry</subject><subject>Spectrometry, Fluorescence</subject><subject>Sustainability</subject><issn>1522-7235</issn><issn>1522-7243</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kdtqFTEUhgdRbK2CTyABb7yZmplkTpdaT4VCb-z1sCZZ6U7NTKY5KLuv2Rdy7e5tBcFASEi-9a_DXxSvK35acV6_n6w_lR2XT4rjqqnrsqulePp4F81R8SLGG85527bD8-JI9FLQao-L-6tknU1b5g27DogLUxucbUxhy4wPLOaYwC4wOWTGZR8wKlwUMo3B_oRk72j7hcG6Bg9qsw9aUaXgH3g7YwpWsdsMS7LGqj1P6T5B8C4nmK1GBpHt_hf0q4OYKECHfM3swtYNhBkUZnoEt9OfszskXTTlsj9Qs02egViKneFl8cyAi_jqcJ4UV18-fz_7Vl5cfj0_-3BRKiEHWfaCd7VSA3RT33PdGyH00Gs0k9RthW2DmutuGFCbDiVMWDUtUCEVNE3dCiNOind7XWr9NmNMIw1OoXNAbeQ41oPoaMii7wh9-w9643NYqDqiukFyIdvmr6AKPsaAZlxpfhC2Y8XHndEjGT3ujCb0zUEwTzPqR_CPswSUe-CXdbj9r9D48fzyQfA3PMW50g</recordid><startdate>202403</startdate><enddate>202403</enddate><creator>Salem, Hesham</creator><creator>Abdelmajed, Mahmoud A.</creator><creator>Rabiey, Mahmoud</creator><creator>Saied, Omar</creator><creator>Amir, Michael</creator><creator>Abdelgalil, Mahmoud</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QF</scope><scope>7QO</scope><scope>7QP</scope><scope>7QQ</scope><scope>7SC</scope><scope>7SE</scope><scope>7SP</scope><scope>7SR</scope><scope>7TA</scope><scope>7TB</scope><scope>7U5</scope><scope>7U7</scope><scope>8BQ</scope><scope>8FD</scope><scope>C1K</scope><scope>F1W</scope><scope>F28</scope><scope>FR3</scope><scope>H8D</scope><scope>H8G</scope><scope>H95</scope><scope>JG9</scope><scope>JQ2</scope><scope>KR7</scope><scope>L.G</scope><scope>L7M</scope><scope>L~C</scope><scope>L~D</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6467-849X</orcidid></search><sort><creationdate>202403</creationdate><title>Utility of green chemistry for sustainable fluorescence derivatization approach for spectrofluorimetric quantification of Darolutamide as antineoplastic drug in pharmaceutical formulation and spiked human plasma</title><author>Salem, Hesham ; Abdelmajed, Mahmoud A. ; Rabiey, Mahmoud ; Saied, Omar ; Amir, Michael ; Abdelgalil, Mahmoud</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3494-83072cc9a7b880d8f33d98defb4d61e65ed0d799edf7e4abe156aace1a55263f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>4-Chloro-7-nitrobenzofurazan</topic><topic>Androgen receptors</topic><topic>Antineoplastic Agents</topic><topic>Blood plasma</topic><topic>Buffers (chemistry)</topic><topic>Cancer</topic><topic>Darolutamide</topic><topic>Drug Compounding</topic><topic>Fluorescence</topic><topic>fluorescence derivatization</topic><topic>Green chemistry</topic><topic>green spectrofluorimetric method</topic><topic>Humans</topic><topic>Male</topic><topic>Metastases</topic><topic>NBD‐Cl</topic><topic>Pharmaceuticals</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms</topic><topic>Pyrazoles</topic><topic>Quality of Life</topic><topic>Spectrofluorimetry</topic><topic>Spectrometry, Fluorescence</topic><topic>Sustainability</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Salem, Hesham</creatorcontrib><creatorcontrib>Abdelmajed, Mahmoud A.</creatorcontrib><creatorcontrib>Rabiey, Mahmoud</creatorcontrib><creatorcontrib>Saied, Omar</creatorcontrib><creatorcontrib>Amir, Michael</creatorcontrib><creatorcontrib>Abdelgalil, Mahmoud</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Aluminium Industry Abstracts</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Ceramic Abstracts</collection><collection>Computer and Information Systems Abstracts</collection><collection>Corrosion Abstracts</collection><collection>Electronics & Communications Abstracts</collection><collection>Engineered Materials Abstracts</collection><collection>Materials Business File</collection><collection>Mechanical & Transportation Engineering Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>Toxicology Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>ANTE: Abstracts in New Technology & Engineering</collection><collection>Engineering Research Database</collection><collection>Aerospace Database</collection><collection>Copper Technical Reference Library</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources</collection><collection>Materials Research Database</collection><collection>ProQuest Computer Science Collection</collection><collection>Civil Engineering Abstracts</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Professional</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>Computer and Information Systems Abstracts Academic</collection><collection>Computer and Information Systems Abstracts Professional</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Luminescence (Chichester, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Salem, Hesham</au><au>Abdelmajed, Mahmoud A.</au><au>Rabiey, Mahmoud</au><au>Saied, Omar</au><au>Amir, Michael</au><au>Abdelgalil, Mahmoud</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Utility of green chemistry for sustainable fluorescence derivatization approach for spectrofluorimetric quantification of Darolutamide as antineoplastic drug in pharmaceutical formulation and spiked human plasma</atitle><jtitle>Luminescence (Chichester, England)</jtitle><addtitle>Luminescence</addtitle><date>2024-03</date><risdate>2024</risdate><volume>39</volume><issue>3</issue><spage>e4704</spage><epage>n/a</epage><pages>e4704-n/a</pages><issn>1522-7235</issn><eissn>1522-7243</eissn><abstract>Darolutamide is an oral nonsteroidal androgen receptor antagonist used to delay the process of prostate cancer to metastatic disease and to increase the quality of life for people with advanced prostate cancer. Here, a second spectrofluorimetric method was advanced for quantifying Darolutamide in pharmaceutical formulation and spiked human plasma. This method depends on the fluorescence derivatization of Darolutamide with 4‐chloro‐7‐nitrobenzo‐2‐oxa‐1,3‐diazole (NBD‐Cl) at 75°C in a (pH 9) of borate buffer to produce a fluorescent derivative that can be detected at 520 nm after excitation at 460 nm. The method has been validated using ICH criteria, and it demonstrated linearity in the range 5–200 ng ml−1. The limit of detection (LOD) and limit of quantitation (LOQ) were 1.15 and 3.84 nm, respectively. The proposed method was applied precisely and accurately for quantifying Darolutamide within the pharmaceutical formulation and spiking human plasma without any interferences. Moreover, the method's sustainability was evaluated and compared with the published method using two greenness assessment tools termed analytical eco‐scale and Analytical GREEnness (AGREE). These findings suggest that the method is more sustainable than the published method.
Darolutamide is an oral nonsteroidal androgen used to delay the process of prostate cancer. A spectrofluorometric method was advanced for quantifying Darolutamide in pharmaceutical formulation and spiked human plasma. The method depends on the fluorescence derivatization of Darolutamide with NBD‐Cl.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38433336</pmid><doi>10.1002/bio.4704</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-6467-849X</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1522-7235 |
ispartof | Luminescence (Chichester, England), 2024-03, Vol.39 (3), p.e4704-n/a |
issn | 1522-7235 1522-7243 |
language | eng |
recordid | cdi_proquest_miscellaneous_2937336387 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | 4-Chloro-7-nitrobenzofurazan Androgen receptors Antineoplastic Agents Blood plasma Buffers (chemistry) Cancer Darolutamide Drug Compounding Fluorescence fluorescence derivatization Green chemistry green spectrofluorimetric method Humans Male Metastases NBD‐Cl Pharmaceuticals Prostate cancer Prostatic Neoplasms Pyrazoles Quality of Life Spectrofluorimetry Spectrometry, Fluorescence Sustainability |
title | Utility of green chemistry for sustainable fluorescence derivatization approach for spectrofluorimetric quantification of Darolutamide as antineoplastic drug in pharmaceutical formulation and spiked human plasma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-16T00%3A06%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Utility%20of%20green%20chemistry%20for%20sustainable%20fluorescence%20derivatization%20approach%20for%20spectrofluorimetric%20quantification%20of%20Darolutamide%20as%20antineoplastic%20drug%20in%20pharmaceutical%20formulation%20and%20spiked%20human%20plasma&rft.jtitle=Luminescence%20(Chichester,%20England)&rft.au=Salem,%20Hesham&rft.date=2024-03&rft.volume=39&rft.issue=3&rft.spage=e4704&rft.epage=n/a&rft.pages=e4704-n/a&rft.issn=1522-7235&rft.eissn=1522-7243&rft_id=info:doi/10.1002/bio.4704&rft_dat=%3Cproquest_cross%3E2979403465%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2979403465&rft_id=info:pmid/38433336&rfr_iscdi=true |